Literature DB >> 6168276

A human choriocarcinoma xenograft in nude mice; a model for the study of antibody localization.

F Searle, J Boden, J C Lewis, K D Bagshawe.   

Abstract

The successful development of the concept of linking cell-killing agents to tumour-specific antibodies will be largely determined by the extent to which the antibodies are preferentially localized in the malignant tissue. A xenograft of human choriocarcinoma (CC3) has been established in nude mice, and the relative distribution of affinity-purified specific antibodies to human chorionic gonadotrophin has been compared with that of nonspecific antibodies from the same species. Treatment of the nonspecific antibodies with ammonium thiocyanate appeared to be important to ensure that the distributions in normal nude mice were equivalent. Specificity indices, derived from the comparative distributions of isotope activity in the tumour and lung of labelled specific and nonspecific antibodies, ranged between 1.3 and 2.0.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6168276      PMCID: PMC2010755          DOI: 10.1038/bjc.1981.163

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

1.  CHORIOCARCINOMA: GROWTH PATTERNS IN HAMSTER TISSUES.

Authors:  R L EHRMANN; L E GLISERMAN
Journal:  Nature       Date:  1964-04-25       Impact factor: 49.962

2.  KARYOTYPIC AND MORPHOLOGIC CHARACTERIZATION OF A SERIALLY TRANSPLANTED HUMAN CHORIOCARCINOMA.

Authors:  M GALTON; P B GOLDMAN; S F HOLT
Journal:  J Natl Cancer Inst       Date:  1963-10       Impact factor: 13.506

3.  A rapid, sensitive and specific radioimmunoassay for human chorionic gonadotrophin.

Authors:  A Kardana; K D Bagshawe
Journal:  J Immunol Methods       Date:  1976       Impact factor: 2.303

4.  Human gastric choriocarcinoma serially transplanted in nude mice.

Authors:  T Kameya; Y Shimosato; M Tumuraya; N Ohsawa; T Nomura
Journal:  J Natl Cancer Inst       Date:  1976-02       Impact factor: 13.506

5.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

6.  Choriocarcinoma scanning using radiolabeled anti-body to chorionic gonadotrophin.

Authors:  J Quinones; G Mizejewski; W H Beierwaltes
Journal:  J Nucl Med       Date:  1971-02       Impact factor: 10.057

7.  Radioimmunolocalization of tumours by external scintigraphy after administration of 131I antibody to human chorionic gonadotrophin: preliminary communication.

Authors:  R H Begent; F Searle; G Stanway; R F Jewkes; B E Jones; P Vernon; K D Bagshawe
Journal:  J R Soc Med       Date:  1980-09       Impact factor: 5.344

8.  Clinical radioimmunodetection of cancer with radioactive antibodies to human chorionic gonadotropin.

Authors:  D M Goldenberg; E E Kim; F H DeLand; J R van Nagell; N Javadpour
Journal:  Science       Date:  1980-06-13       Impact factor: 47.728

9.  Regional differences in the incidence and growth of mouse tumors following intradermal or subcutaneous inoculation.

Authors:  R Auerbach; L W Morrissey; Y A Sidky
Journal:  Cancer Res       Date:  1978-06       Impact factor: 12.701

10.  Localization of GW-39 human tumors in hamsters by affinity-purified antibody to carcinoembryonic antigen.

Authors:  F J Primus; R Macdonald; D M Goldenberg; H J Hansen
Journal:  Cancer Res       Date:  1977-05       Impact factor: 12.701

View more
  11 in total

Review 1.  Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.

Authors:  C H Ford; A G Casson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Monoclonal antibody to an intracellular antigen images human melanoma transplants in nu/nu mice.

Authors:  S Welt; M J Mattes; R Grando; T M Thomson; R W Leonard; P B Zanzonico; R E Bigler; S Yeh; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

3.  Activity and distribution studies of etoposide and mitozolomide in vivo and in vitro against human choriocarcinoma cell lines.

Authors:  C J Brindley; R B Pedley; P Antoniw; E S Newlands
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Distribution of intact and Fab2(1) fragments of anti-human chorionic gonadotrophin antibodies in nude mice bearing human choriocarcinoma xenografts.

Authors:  F Searle; T Adam; J A Boden
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

Review 5.  The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites.

Authors:  K D Bagshawe
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

6.  The potential of carboxypeptidase G2: antibody conjugates as anti-tumour agents. II. In vivo localising and clearance properties in a choriocarcinoma model.

Authors:  R G Melton; F Searle; R F Sherwood; K D Bagshawe; J A Boden
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

7.  Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice.

Authors:  P Antoniw; C J Springer; K D Bagshawe; F Searle; R G Melton; G T Rogers; P J Burke; R F Sherwood
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

8.  A cytotoxic agent can be generated selectively at cancer sites.

Authors:  K D Bagshawe; C J Springer; F Searle; P Antoniw; S K Sharma; R G Melton; R F Sherwood
Journal:  Br J Cancer       Date:  1988-12       Impact factor: 7.640

9.  The potential of carboxypeptidase G2-antibody conjugates as anti-tumour agents. I. Preparation of antihuman chorionic gonadotrophin-carboxypeptidase G2 and cytotoxicity of the conjugate against JAR choriocarcinoma cells in vitro.

Authors:  F Searle; C Bier; R G Buckley; S Newman; R B Pedley; K D Bagshawe; R G Melton; S M Alwan; R F Sherwood
Journal:  Br J Cancer       Date:  1986-03       Impact factor: 7.640

10.  Third Gordon Hamilton-Fairley Memorial Lecture. Tumour markers--where do we go from here?

Authors:  K D Bagshawe
Journal:  Br J Cancer       Date:  1983-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.